1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
6
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Cellular Bioengineering, Inc. is a company with 1 orphan drug designation across 6 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Fuchs' endothelial dystrophy | Autologous cultured endothelial cells on a donor human corneal disk | Des.TrialAppr. |
| bullous keratopathy | Autologous cultured endothelial cells on a donor human corneal disk | Des.TrialAppr. |
| corneal dystrophy, Fuchs endothelial, 1 | Autologous cultured endothelial cells on a donor human corneal disk | Des.TrialAppr. |
| corneal dystrophy, Fuchs endothelial, 3 | Autologous cultured endothelial cells on a donor human corneal disk | Des.TrialAppr. |
| corneal dystrophy, Fuchs endothelial, 4 | Autologous cultured endothelial cells on a donor human corneal disk | Des.TrialAppr. |
| corneal dystrophy, Fuchs endothelial, 6 | Autologous cultured endothelial cells on a donor human corneal disk | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio